

HR 1432

Preserve Access to Affordable Generics Act

Congress: 110 (2007–2009, Ended)

Chamber: House

Policy Area: Commerce

Introduced: Mar 9, 2007

Current Status: Referred to the Subcommittee on Commerce, Trade and Consumer Protection.

Latest Action: Referred to the Subcommittee on Commerce, Trade and Consumer Protection. (Mar 12, 2007)

Official Text: <https://www.congress.gov/bill/110th-congress/house-bill/1432>

Sponsor

Name: Rep. Waxman, Henry A. [D-CA-30]

Party: Democratic • State: CA • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Van Hollen, Chris [D-MD-8]	D · MD		Sep 24, 2007

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 12, 2007
Judiciary Committee	House	Referred To	Mar 9, 2007

Subjects & Policy Tags

Policy Area:

Commerce

Related Bills

Bill	Relationship	Last Action
110 S 316	Related bill	Mar 7, 2007: Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Hearings held.

Preserve Access to Affordable Generics Act - Amends the Clayton Act to make it unlawful for a person, in connection with the sale of a drug product, to be a party to any agreement resolving or settling a patent infringement claim in which: (1) an abbreviated new drug (generic) application filer receives anything of value; and (2) such filer agrees not to research, develop, manufacture, market, or sell the generic product for any period. Excludes a resolution or settlement that includes no more than the right to market the generic product prior to the expiration of the patent.

Amends the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to set forth additional filing requirements related to agreements between a brand name drug company and a generic drug applicant. Requires the Chief Executive Officer or the company official responsible for negotiating any agreement to file a certification that materials filed with respect to such agreements are complete, final, and exclusive.

Amends the Federal Food, Drug, and Cosmetic Act to provide that forfeiture of the 180-day exclusivity period for the marketing of a generic drug occurs if there is a final decision of the Federal Trade Commission (FTC) or the court that an agreement has violated this Act.

Actions Timeline

- **Mar 12, 2007:** Referred to the Subcommittee on Commerce, Trade and Consumer Protection.
- **Mar 9, 2007:** Introduced in House
- **Mar 9, 2007:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.